Navigation Links
Genelabs Technologies Announces Commitments to Raise $23.7 Million in a Registered Direct Financing
Date:9/26/2007

Funds to Support Ongoing HCV Drug Discovery Projects

REDWOOD CITY, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that it has obtained commitments from several institutional investors to purchase approximately 12.9 million shares of its common stock and warrants to purchase approximately 2.6 million shares of its common stock for gross proceeds of approximately $23.7 million. The investors have agreed to purchase the shares and warrants for $1.84 per unit (each unit consisting of one share and a warrant to purchase 0.20 shares of common stock). The exercise price of the warrants will be $2.08 per share. The warrants will be exercisable at any time prior to the fifth anniversary of the closing of the transaction. The closing of the offering is expected to take place on October 1, 2007, subject to satisfaction of customary closing conditions. Genelabs plans to use the proceeds from this financing to support its ongoing hepatitis C virus (HCV) drug discovery programs and for general corporate purposes. The proceeds will not be used to fund a new phase III clinical trial of Prestara. Deutsche Bank Securities Inc. acted as exclusive placement agent in the transaction.

A shelf registration statement relating to these securities (File No. 333-145497) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement when filed, can be obtained at the Securities and Exchange Commission's website, http://www.sec.gov, or from Genelabs.

Contact: James A. D. Smith

President and Chief Executive Officer

Phone: 650-562-1424


'/>"/>
SOURCE Genelabs Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers Develop Technologies to Devour Food Pathogens
2. Researchers Study Safety of Assisted Reproductive Technologies
3. India to Propose Global Fund for Clean Energy Technologies
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors to ... Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip ... zones. Editors can select from a variety of flip book animations. In Addition, users ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, ... at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of ... acupuncturists to help patients realize their family building goals. Acupuncture helps fertility ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
(Date:12/7/2016)... ... December 07, 2016 , ... The ... Architecture Innovation Summit in Reston, VA on March 21-22, 2017. This premier event ... range of experiences from a cross-section of industries such as financial services, insurance, ...
(Date:12/7/2016)... Warwick, New York (PRWEB) , ... December 07, 2016 , ... ... computer professor at Yale had described him as 'a genius.'" Thus begins "Margaret in ... R. L. Rhyse and published by Wyston Books, Inc. These novels narrate ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 Diplomat Pharmacy, Inc. (NYSE: ... five subsidiaries—American Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, ... specialty infusion services, visit diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat ... "As we continue to build ...
(Date:12/7/2016)... SCIENCE PARK , Israel , ... (TASE: KDST) announced today the signing of a memorandum of understanding ... companies. The synergy between the companies will assist in expediting Kadimastem,s ... worldwide leader in innovative treatment for severe diseases in general and ... , ...
(Date:12/7/2016)...  Based on its recent analysis of ... Sullivan recognizes Nemaura Pharma Limited with the ... Enabling Technology Leadership. Nemaura Pharma,s transdermal drug ... drug delivery technologies, especially in delivering biologics. ... technologies, Memspatch and Micropatch respectively, facilitate minimally ...
Breaking Medicine Technology: